Stevens Capital Management LP Acquires 286 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Stevens Capital Management LP lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.3% during the 4th quarter, Holdings Channel reports. The firm owned 1,570 shares of the company’s stock after purchasing an additional 286 shares during the quarter. Stevens Capital Management LP’s holdings in IDEXX Laboratories were worth $871,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in IDXX. Gotham Asset Management LLC raised its stake in shares of IDEXX Laboratories by 79.9% in the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock worth $7,620,000 after purchasing an additional 7,741 shares during the last quarter. NewEdge Wealth LLC increased its position in shares of IDEXX Laboratories by 30.4% during the third quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock valued at $279,000 after acquiring an additional 149 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of IDEXX Laboratories by 25.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock valued at $24,196,000 after acquiring an additional 8,831 shares during the last quarter. Carderock Capital Management Inc. increased its position in shares of IDEXX Laboratories by 35.7% during the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock valued at $9,112,000 after acquiring an additional 4,315 shares during the last quarter. Finally, Mitchell Capital Management Co. increased its position in shares of IDEXX Laboratories by 1.3% during the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock valued at $2,786,000 after acquiring an additional 79 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on IDXX shares. Barclays increased their price target on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. JPMorgan Chase & Co. raised their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a research report on Tuesday, January 30th. Finally, The Goldman Sachs Group lifted their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Insider Buying and Selling

In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,524 shares of company stock valued at $24,871,960. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Stock Down 1.0 %

NASDAQ IDXX traded down $5.02 during mid-day trading on Thursday, reaching $489.24. The stock had a trading volume of 358,450 shares, compared to its average volume of 430,629. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The stock has a market cap of $40.63 billion, a PE ratio of 49.08, a price-to-earnings-growth ratio of 3.80 and a beta of 1.26. The company has a fifty day moving average price of $533.74 and a 200 day moving average price of $510.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.05 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.